X

Drug Profile

ORIC 613

Alternative Names: ORIC-613; ORIC613 - ORIC Pharmaceuticals

Latest Information Update: 16 Apr 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator ORIC Pharmaceuticals
Class Antineoplastics; Small molecules
Mechanism of Action PLK4 protein inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Breast cancer

Most Recent Events

08 Apr 2024 Pharmacodynamics data from preclinical studies in Prostate cancer released by RIC Pharmaceuticals
05 Mar 2024 Pharmacodynamics data from a preclinical trial in Breast cancer released by ORIC Pharmaceuticals
08 Jan 2024 Preclinical trials in Breast cancer in USA (PO) prior to January 2024

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com